Upcoming event

Active surveillance in nonhereditary bilateral multifocal type i papillary renal cell carcinoma

Journal of Urology, September 2021

Impact of surgical approach (open vs. minimally invasive) on oncological outcomes after nephrectomy for localised renal cell carcinoma: a recur database project

Journal of Urology, September 2021

Surgeon-specific variation in operative outcomes for patients with clinical T1 renal masses

Journal of Urology, September 2021

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study

The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management

European Urology, Volume 79, Issue 4, April 2021, Pages 468-477

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)

Indocyanine green guidance during 3D augmented reality robot assisted partial nephrectomy: A step towards the “automatic” overlapping

New technologies in robot-assisted kidney transplantation: Improving surgical performances, expanding the indication

Robot-assisted partial nephrectomy with 3D preoperative surgical planning: Video presentation of the florentine experience

Essential research priorities in renal cancer: a modified delphi consensus statement

European Urology Focus, September 2021

Predicting intra‐operative and postoperative consequential events using machine‐learning techniques in patients undergoing robot‐assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study

BJU International, April 2021

PreviousNext